Belgium· BE-AMP-SAM595484-00
Rybrevant 350 mg
A amivantamab product containing amivantamab, registered in Belgium by Janssen-Cilag International. The same ATC class is registered in 15 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Amivantamab is registered in 15 of 19 countries.
Countries holding a registration under ATC L01FX18 (amivantamab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Amivantamab · ATC L01FX18
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of amivantamab costs, country by country.
Normalised to the WHO defined daily dose (75 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Amivantamab · price per daily dose (75 mg)
USD · FX 28 Sept 2026
- CH Switzerland$335.64
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Amivantamab
- Manufacturer
- Janssen-Cilag International
- Country
- Belgium (BE)
- ATC code
- L01FX18
- ATC class
- Amivantamab
- Defined daily dose
- 75 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb4430674
- be_apb7749385
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Amivantamab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaRYBREVANTJanssen-Cilag International N.V., Beerse
- FinlandRybrevantJanssen-Cilag International NV
- IrelandRybrevant 350 mg concentrate for solution for infusionJanssen-Cilag International NV
- IcelandRybrevantJanssen-Cilag International NV*
- PolandRybrevantJanssen-Cilag International N.V.
- SwedenRybrevant 350 mg Koncentrat till infusionsvätska, lösningJanssen-Cilag International NV
- NorwayRybrevantJanssen-Cilag International N.V.
- NetherlandsRybrevant 1600 mg, oplossing voor injectieJanssen-Cilag International NV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rybrevant
- Liechtenstein · Rybrevant
- Norway · Rybrevant
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ffac0032-b9c4-4342-963d-3bd657a85753 GET /v1/drugs/ffac0032-b9c4-4342-963d-3bd657a85753?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Rybrevant 350 mg",
"name_fr": "Rybrevant 350 mg",
"name_nl": "Rybrevant 350 mg",
"amp_code": "SAM595484-00",
"strengths": [
"50.0000"
],
"pack_count": 1,
"substances": [
"Amivantamab",
"Disodium Ethylenediaminetetraacetic Acid (EDTA) Dihydrate",
"Sucrose",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Amivantamab",
"authorisation_numbers": [
"EU/1/21/1594/001"
]
}See everything about amivantamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.